Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Glaxosmithkline Plc ADR (GSK)

Glaxosmithkline Plc ADR (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,643,648
  • Shares Outstanding, K 2,541,795
  • Annual Sales, $ 46,910 M
  • Annual Income, $ 6,030 M
  • 60-Month Beta 0.64
  • Price/Sales 2.40
  • Price/Cash Flow 15.34
  • Price/Book 3.71
Trade GSK with:

Options Overview Details

View History
  • Implied Volatility 22.74% ( +1.57%)
  • Historical Volatility 20.74%
  • IV Percentile 66%
  • IV Rank 24.51%
  • IV High 43.90% on 01/05/22
  • IV Low 15.88% on 08/27/21
  • Put/Call Vol Ratio 0.72
  • Today's Volume 471
  • Volume Avg (30-Day) 2,295
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 179,725
  • Open Int (30-Day) 173,594

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 0.68
  • Number of Estimates 2
  • High Estimate 0.69
  • Low Estimate 0.66
  • Prior Year 0.79
  • Growth Rate Est. (year over year) -13.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.13 +4.78%
on 05/12/22
46.25 -4.54%
on 04/19/22
-2.05 (-4.44%)
since 04/18/22
3-Month
39.22 +12.58%
on 03/07/22
46.97 -6.00%
on 04/11/22
+1.11 (+2.58%)
since 02/18/22
52-Week
37.80 +16.80%
on 10/06/21
46.97 -6.00%
on 04/11/22
+4.59 (+11.60%)
since 05/18/21

Most Recent Stories

More News
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold

Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.

GSK : 44.18 (-1.19%)
GERN : 1.3400 (-5.63%)
ALKS : 29.09 (-2.02%)
GILD : 63.74 (+0.89%)
3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure,...

GILD : 63.74 (+0.89%)
GSK : 44.18 (-1.19%)
TAK : 14.23 (-0.56%)
Was This Acquisition a Smart Move for GlaxoSmithKline?

The British drugmaker recently announced that it agreed to acquire a late-stage biopharmaceutical company.

GSK : 44.18 (-1.19%)
Why GSK May Have Bet Too Big on a Pandemic Pipeline

Its late-stage pipeline is heavily weighted toward pandemic treatments.

GSK : 44.18 (-1.19%)
SNY : 52.97 (+0.13%)
PFE : 50.53 (-1.58%)
MRNA : 139.75 (-1.78%)
AZN : 64.04 (-2.44%)
NVAX : 51.16 (-1.52%)
3 High-Yield Dividend Stocks to Buy in May: GlaxoSmithKline, A.P. Moeller-Maersk, and ENI

With the latest federal interest rate hike and the possibility of further monetary policy tightening, market indices have been going haywire. Because volatility is expected to persist, with experts fearing...

AMKBY : 14.3200 (-2.55%)
E : 28.89 (-1.06%)
GSK : 44.18 (-1.19%)
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline...

SRRA : 54.62 (-0.04%)
GSK : 44.18 (-1.19%)
Does OrganiGram Holdings Deserve a Place in Your Cannabis Portfolio?

The cannabis industry has attracted significant investor attention over the past couple of years due to its growing use for both medical and recreational purposes. Also, the increasing legalization of...

GSK : 44.18 (-1.19%)
MRK : 92.95 (-0.05%)
NVO : 103.91 (-2.29%)
OGI : 1.2500 (-6.02%)
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA

Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will...

SRRA : 54.62 (-0.04%)
GSK : 44.18 (-1.19%)
Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales

Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.

GSK : 44.18 (-1.19%)
GILD : 63.74 (+0.89%)
VRTX : 254.50 (-2.80%)
VYGR : 6.28 (-4.27%)
Will Johnson & Johnson Continue Trending Higher This Year?

The COVID-19 pandemic has given a boost to the pharmaceutical industry's revenues. And pharmaceutical companies are expected to remain in focus by investors as the demand for medicines rises with an increase...

GSK : 44.18 (-1.19%)
JNJ : 177.68 (-0.64%)
NVS : 88.02 (+0.11%)
ZTS : 162.21 (-2.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Glaxo has 3 core businesses - Pharmaceuticals, Vaccines and Consumer Healthcare. The company has made significant progress in expanding its presence in emerging markets by acquiring product portfolios from companies like Bristol-Myers and UCB. In August 2019, Glaxo and Pfizer merged their consumer healthcare...

See More

Key Turning Points

3rd Resistance Point 45.45
2nd Resistance Point 45.18
1st Resistance Point 44.94
Last Price 44.18
1st Support Level 44.44
2nd Support Level 44.17
3rd Support Level 43.93

See More

52-Week High 46.97
Last Price 44.18
Fibonacci 61.8% 43.47
Fibonacci 50% 42.38
Fibonacci 38.2% 41.30
52-Week Low 37.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar